Everolimus Tab. not checked

Chong Kun Dang Pharmaceutical

FollowEvery change as it happens, and a Monday email
Stage
in other
Next date
Phase 4 trial completes
Trials
19 active
23 in total · 21 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Up to 1.5g BID(total 3g daily), PO - Check the blood concentration of Everolimus at each visit”In the company’s words, NCT06942156 on ClinicalTrials.gov
Tested for
Heart Transplant
Main trialPhase 4
“The purpose of this study is to evaluate the efficacy and safety of lower dose calcineurin inhibitors (CNI) in combination with Everolimus in Korean heart transplant recipients.”In the company’s words, NCT06942156 on ClinicalTrials.gov
Other names
CertiroBell Tab. · Everolimus

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials23

TrialPhaseCompletesWhat it tests
Phase 4Not yet recruiting Dec 2030 Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Phase 4Completed 24 Jul 2024 Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.
Phase 3Authorised not given Efficacy, safety and patient-reported outcomes of peptide receptor radionuclide therapy with 177Lu-edotreotide compared to everolimus in somatostatin receptor positive neuroendocrine tumors of the lung and thymus. The LEVEL trial
Phase 3/4Ended not given Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
Phase 2Authorised not given Individualized everolimus therapy in metastatic breast cancer
Phase 3Authorised not given Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication: BIOMEDE 2.0
Phase 2Ended not given Targeting mTOR with everolimus and/or physical training for preventing postmenopausal bone loss and accelerated skeletal aging. The RapaLoad study.
Phase 2Authorised not given Evaluation of the addition of Everolimus to 177Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical trial
Phase 4Authorised not given zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention
Phase 2Authorised not given Repurposing Everolimus to enhance musculoskeletal Vitality and Ageing in The Elderly (RENOVATE)
Phase 2Authorised not given An open-label single arm interventional phase 2 study to investigate outcome of individualized treatment based on pharmacogenomic profiling and ex vivo drug sensitivity testing of patient-derived organoids in patients with metastatic colorectal cancer
Phase 3Authorised not given A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study-
Phase 4Authorised not given Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR)
Phase 1/2Authorised not given AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 3Authorised not given UNIRAD : Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease
Phase 4Ended not given The OPTIMIzE study;OPen label multicenter randomized Trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
Phase 2Authorised not given A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Phase 4Authorised not given Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation
Phase 2Authorised not given Resistance training and rapamycin to enhance bone formation in postmenopausal women (STRONGBONE)
Phase 4Authorised not given Randomized study evaluating the impact of an innovative and cooperative pathway integrating oncogeriatric, pharmaceutical and pharmacological follow-up in elderly patients (>70 years old) presenting with cancer and treated with oral therapy _ POG
Phase 1Authorised not given Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma; MEDWAY
Phase 3Authorised not given Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe year AfTer lIver transplantatiON (ALTERNATION) – a randomized, prospective, multicenter, open-label, controlled phase III trial
Phase 4Authorised not given HORUS-Cytomegalovirus Open Proof-of-concept Exploratory trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Everolimus Tab.

Following is part of Solo: you see every change to Everolimus Tab. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in